infectious diseases
Mosquito-Borne Pathogen Research Services
Preclinical Mosquito-Borne Virus and Parasite Research Services
Climate change is exacerbating the threat from mosquito-borne diseases around the world. At BIOQUAL, we have decades of experience delivering in vitro and in vivo preclinical research studies for mosquito-borne pathogens, including Chikungunya, Mayaro, and malaria.
We offer a wide range of relevant animal models and in vitro assays to support the development of novel vaccines and therapeutics for mosquito-borne infections, as well as custom model and assay development. Our highly experienced team and secure facilities up to Biosafety Level 3 (BSL-3) provide the highest safety standards for working with high-risk wild-type pathogens, and can rapidly adapt to meet emerging global health threats.
Mosquito-Borne Pathogen Research Capabilities
BIOQUAL offers a full range of in vivo and in vitro preclinical research services to support the development of novel vaccines and therapeutics for mosquito-borne viruses and parasites. We have BSL-2 facilities for research into malaria, Dengue, Zika, and Mayaro, and BSL-3 for Chikungunya. Our services include:
In Vivo Mosquito-Borne Pathogen Models
We offer a range of in vivo models for mosquito-borne infections, including mice and NHPs, to enable in-depth study of infection mechanisms, immune responses, and therapeutic efficacy. Whatever the pathogen, our team draws on decades of hands-on experience to help you choose the right model for your research question or develop a new one if none exists.
In Vitro Mosquito-Borne Pathogen Assays
We provide extensive laboratory services including in vitro viral load testing, serological testing, and characterization of immune responses to mosquito-borne viruses and parasites. We use our proven methodologies and scientific expertise to optimize existing assays and develop customized procedures, delivering accurate, consistent results that support robust decision-making along the preclinical journey.
Integrated Preclinical Research Capabilities
By integrating in vitro laboratory services with small and large animal models, BIOQUAL supports preclinical research at every stage from the lab to the clinic, driving efficiency and ensuring regulatory compliance. Our clients benefit from expert advice, consistent methodologies, and high quality standards to advance therapeutic and vaccine candidates confidently toward clinical development.
Mosquito-Borne Virus and Parasite Models
We offer a wide range of relevant animal models for mosquito-borne viruses and parasites, including Zika, dengue, chikungunya, Mayaro and malaria, as well as custom model development. We also have a tick-borne Heartland virus model to support research against this emerging pathogen.
Rodent Models for Mosquito-Borne Viruses
- IFNAR-/- mice
- AG129 immunocompromised mice
- BALB/c mice
- C57BL/6 mice
NHP Models for Mosquito-Borne Viruses
- African green monkeys
- Rhesus macaques
- Cynomolgus macaques
Malaria Animal Models
- BALB/c mice
- CD-1 mice
- Rhesus macaques
- Squirrel monkeys
Mosquito-Borne Virus and Parasite Assays
We offer a wide range of in vitro assays aimed at understanding viral- or vaccine-induced immune responses to mosquito-borne pathogens including Zika, Dengue, Chikungunya, Mayaro, and malaria.
Our standard preclinical assay services range from binding antibody and neutralization assays and viral load testing to detailed immune cell characterization. We are also happy to work with our clients to develop custom assays to support the development of novel vaccines and antivirals.
Sample Processing
We receive and process samples infected with mosquito-borne pathogens safely and securely.
Viral Load Testing
We offer qRT-PCR and plaque assays for viral load testing.
Binding Antibody and Neutralization Assays
We offer binding antibody ELISA and neutralization assays such as plaque reduction neutralization test (PRNT).
Immune Response Characterization
We offer flow cytometry characterization and functional assays of immune cell populations in response to mosquito-borne pathogen infection or vaccination, as well as cytokine/chemokine detection and analysis using ELISpot, Luminex, and ELISA.
Parasite Detection and Identification
We can detect and identify malaria parasites in Giemsa–stained blood smears.
Serological Testing
We provide ELISA assay serological testing for immune responses to mosquito-borne pathogens.
Integrated Preclinical Research Capabilities
At BIOQUAL, we know that innovative science needs solid support at every step of the journey from the lab to the clinic. Our preclinical research services range from early-stage in vitro assays and screening through to critical in vivo studies in a wide range of animal models, ensuring our partners have the robust, reliable data they need to advance groundbreaking vaccine and therapeutic research programs.
Don’t see the model or assay you need? Talk to our scientists about our custom solutions.
Why Work With BIOQUAL
With more than four decades of experience, BIOQUAL is the expert preclinical CRO specializing in infectious disease and immunology. We are trusted by hundreds of clients across government, biopharma, and academic research institutes to deliver the quality, safety, and flexibility that they demand.
Our highly experienced team and state-of-the-art Biosafety Level 3 facilities provide the highest safety standards for working with high-risk wild-type pathogens. And our AAALAC accreditation demonstrates our dedication to humane and compliant animal care, prioritizing welfare and establishing a reliable foundation for producing high-quality research data.
Every preclinical research program comes with its own timeline, budget, and scientific challenges, so we work closely with our clients to develop tailored approaches that meet the specific needs of each study. We have the flexibility to adapt to changing demands and shifting priorities, and a proven track record of moving fast in response to rapidly emerging public health threats.
Mosquito-Borne Pathogen Research Publications
Developing a Novel Zika Vaccine
We carried out preclinical studies in rodents to support the development of a Zika vaccine that does not cause cross-reactivity with other similar viral infections
Testing a Novel mRNA LNP Zika Vaccine
We showed that a single dose of an mRNA lipid nanoparticle (LNP) vaccine could give rhesus macaques long-term immunity to Zika virus – technology that underpinned the Pfizer-BioNTech Comirnaty SARS-CoV-2 mRNA vaccine.


